16 recruiting, 7 withdrawn, 6 active not recruiting, 6 unknown. 43 Phase 2, 21 Phase 1, 1 Phase 3.
Follow B-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of B-cell Acute Lymphoblastic Leukemia trials Research Report on B-cell Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-12-01 | 2026-11-09 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-11-10 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2026-01-30 | 2026-08-18 |
| Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Liping Dou | 20 | 2026-01-01 | 2026-06-15 |
| Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Liping Dou | 30 | 2026-01-01 | 2026-06-25 |
| A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) HY004, Cyclophosphamide, Fludarabine Phosphate - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Juventas Cell Therapy Ltd. | 2025-06-30 | 2025-08-08 | |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Study of YK012 in B-cell Acute Lymphoblastic Leukemia YK012 - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Excyte Biopharma Ltd | 46 | 2024-09-25 | 2026-02-06 |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) Zilovertamab vedotin - B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 90 | 2024-08-16 | 2026-10-30 |
| Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. Inaticabtagene autoleucel - B-cell Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2024-08-01 | 2024-11-05 |
| Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL Decitabine, venetoclax and blinatumomab - B-cell Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 30 | 2024-04-25 | 2024-11-19 |
| A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) single dose of CNCT19 - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Juventas Cell Therapy Ltd. | 47 | 2023-02-07 | 2025-08-12 |
| Co-administration of CART22-65s and huCART19 for B-ALL Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s), Autologous, humanized anti-CD19 CAR T cell therapy (huCART19) - B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Recruiting | Stephan Grupp MD PhD | 93 | 2023-01-25 | 2026-03-27 |
| Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL UCAR-T Cells - B-cell Acute Lymphoblastic Leukemia, B-ALL | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 30 | 2022-12-05 | 2022-12-08 |
| CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma CD19 CAR T-Cell(CAT19T2) - B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified | Phase 1 / Phase 2 | Withdrawn | Zhujiang Hospital | 2022-12-01 | 2024-03-18 | |
| Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL U-CAR-T Cells (LstCAR019) - B-cell Acute Lymphoblastic Leukemia, B-ALL | Phase 1 / Phase 2 | Withdrawn | Kunming Hope of Health Hospital | 2022-10-01 | 2022-11-30 | |
| A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) Tisagenlecleucel - B-cell Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2022-07-12 | 2026-02-04 |
| CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Anti-CD19 CAR T-cells - Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children | Phase 2 | Recruiting | KK Women's and Children's Hospital | 40 | 2022-03-15 | 2023-03-09 |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL IDEAL2 Intervention - B-cell Acute Lymphoblastic Leukemia, Obesity | Phase 2 | Recruiting | Etan Orgel | 240 | 2022-03-12 | 2026-08-19 |
Showing 20 of 43. Sign in to see all of them.
Burkitt Lymphoma (43) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Recurrence (6) · Leukemia (4) · Lymphoma (4) · Lymphoma, B-Cell (4) · Neoplasm, Residual (4) · Lymphoma, Large B-Cell, Diffuse (3) · Leukemia, B-Cell (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Leukemia, Biphenotypic, Acute (1)
DNA Virus Infections (43) · Epstein-Barr Virus Infections (43) · Hemic and Lymphatic Diseases (43) · Herpesviridae Infections (43) · Immune System Diseases (43) · Immunoproliferative Disorders (43) · Infections (43) · Neoplasms by Histologic Type (43) · Tumor Virus Infections (43) · Virus Diseases (43) · Lymphatic Diseases (42) · Lymphoma, Non-Hodgkin (42) · Lymphoproliferative Disorders (42) · Neoplasms (42) · Lymphoma (39)
blinatumomab (10) · tisagenlecleucel (6) · Dexamethasone (3) · Immunotherapy, Adoptive (3) · Cyclophosphamide (2) · tocilizumab (2) · Acetaminophen (1) · Alemtuzumab (1) · Azacitidine (1) · Cytarabine (1) · Decitabine (1) · Diphenhydramine (1) · Etoposide (1) · Injections (1) · Inotuzumab Ozogamicin (1)
Novartis Pharmaceuticals (4) · The First Affiliated Hospital of Soochow University (4) · Juventas Cell Therapy Ltd. (2) · Liping Dou (2) · Memorial Sloan Kettering Cancer Center (2) · Merck Sharp & Dohme LLC (2) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · Abramson Cancer Center at Penn Medicine (1) · Amgen Research (Munich) GmbH (1) · Autolus Limited (1) · BeOne Medicines (1) · Beijing Tongren Hospital (1) · BioCryst Pharmaceuticals (1) · Cellectis S.A. (1) · Dorothy Sipkins, MD, PhD (1)
United States (17) · China (16) · France (6) · Italy (5) · Spain (5) · Belgium (4) · Canada (4) · Germany (4) · Netherlands (4) · United Kingdom (4) · Denmark (3) · Sweden (3) · Australia (2) · Austria (2) · Greece (2)
Abdel-Azim Hisham, MD (1) · Aloysius Ho, MD (1) · Christian Schmidt, MD (1) · Dorothy Sipkins, MD (1) · Elias Jabbour, MD (1) · Jae Park, MD (1) · Jianxiang Wang M.D. (1) · Jie Jin, MD (1) · Kevin Curran, MD (1) · Li Li, MD (1) · Lihua Yang (1) · Marion Subklewe, MD (1) · Michael Burke, MD (1)
PMID 41671463, PMID 33496754, PMID 34353848, PMID 34432863, PMID 35422096, PMID 27209293, PMID 29358182, PMID 29385370, PMID 30254079, PMID 31606419, PMID 32589970, PMID 32619115, PMID 33843815, PMID 34893603, PMID 36399695, PMID 36821767, PMID 38135369, PMID 41199560, PMID 42525896
2017 (2), 2023 (2), 2015 (1), 2016 (1), 2025 (1)